摘要
目的:探讨齐拉西酮与利培酮治疗精神分裂症的疗效和安全性。方法:将60例精神分裂症患者随机分为齐拉西酮组和利培酮组,每组30例。疗程8周,采用阳性与阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:齐拉西酮组有效率83.3%,显效率70.0%,利培酮组有效率86.7%,显效率73.3%。结论:齐拉西酮治疗精神分裂症疗效较好与利培酮相当,不良反应少。
Objective:To explore the efficacy and safety of ziprasidone in treatment of schizophrenia. Methods:60 patients with schizophreia were randomly assigned two groups ziprasidone group (n = 30) and respenridone group (n = 30) for 8 week. Positive and negative syndrome scale (PANSS) and treatment side effect scale (TESS)were used to evaluate the efficacy and side effects respectively. Results: The response rate and marked response rate was 83.3% andT0.0% in ziprasidone treatment patients,and which was 86.7% and 73.3% in risperidone randomly patients. Conclusions: Ziprasidone has better treatment efficacy and less adverse effects in schizophrenia.
出处
《中国民康医学》
2008年第17期2002-2002,2004,共2页
Medical Journal of Chinese People’s Health